Identifying Breast Cancer Patients Likely to Respond to Chemotherapy
Whole-genome sequencing may help identify the patients who are most likely to benefit from certain types of chemotherapy.
Progress Against Cancer
Whole-genome sequencing may help identify the patients who are most likely to benefit from certain types of chemotherapy.
Thyroid cancer survivors – especially those diagnosed before age 40 – have elevated risk for several aging-related diseases.
A Q&A with medical oncologist Patricia Ganz on chemotherapy-related nerve damage.
More Americans are beating childhood cancer, but many experience effects later in life such as high blood pressure.
Study: Urban native populations may have decreased survival following invasive prostate and breast cancer. Urban American Indians and Alaskan Natives (AIAN) appear to have lower survival rates following invasive prostate and breast cancer as...
Study: Non-obese diabetic African-American women may have a higher risk of developing ER-negative breast cancer.
The type of fat and its location in the body appear to play a role in the risk of developing cancer, a study in the AACR journal Cancer Prevention Research.
The FDA expanded the use of a targeted therapy to include certain patients with two types of non-Hodgkin lymphoma.
The FDA approved a molecularly targeted therapeutic for adults with mantle cell lymphoma that has progressed despite at least one prior treatment.
The FDA approved the second of a revolutionary new type of immunotherapy known as chimeric antigen receptor (CAR) T-cell therapy.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More